Description
The debate highlighted that SCFAs have limited blood-brain barrier penetrance, but specific CNS concentration thresholds for therapeutic efficacy remain unknown. This dosing gap is critical for developing viable gut-brain axis interventions.
Source: Debate session sess_gut-brain-ad (Analysis: gut-brain-ad)